{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-104546","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.579906+00:00","generated_at":"2026-05-17T17:44:17.828798+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amylyx Q2 net loss narrows to $41.4M; cash $180.8M; pipeline milestones on track","bullets":["Net loss of $41.4M ($0.46 per share) vs $72.7M ($1.07) in Q2 2024; lower SG&A and R&D spend in ALS.","Cash, equivalents, and marketable securities $180.8M at June 30, 2025; runway expected through end of 2026.","Pivotal Phase 3 LUCIDITY trial of avexitide in PBH fully enrolled in 2025; topline data H1 2026; potential launch 2027.","Phase 2b ORION trial (AMX0035) in PSP unblinded analysis expected Q3 2025 to inform Phase 3 go/no-go.","FDA Fast Track granted for AMX0114 (antisense oligo) in ALS; early LUMINA Phase 1 data expected 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-104546","json":"https://secwatch.observer/filing/0000950170-25-104546.json","markdown":"https://secwatch.observer/filing/0000950170-25-104546.md","text":"https://secwatch.observer/filing/0000950170-25-104546.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/0000950170-25-104546-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025104546/amlx-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T17:44:17.828798+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}